



PATENT  
Atty. Docket No. 16166.003

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Sidney Wolfe et al.

Serial No.: 10/010,448

Group Art Unit: 1646

Filed: November 7, 2001

Examiner: Janet L. Andres

For: STABILIZED INTERFERON COMPOSITIONS

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56, §1.97 AND §1.98**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

The citations listed on the enclosed Supplemental Information Disclosure Form PTO-1449 may be material to the examination of the above-identified patent application. Therefore, Applicants submit these documents in compliance with the duty of disclosure as defined in 37 C.F.R. §1.56, §1.97 and §1.98. The Examiner is requested to make these citations of official record in the present application.

The present Supplemental Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits. Therefore, Applicants enclose herewith the \$180.00 fee set forth under §1.17(p).

I hereby certify that this correspondence is being deposited  
with the United States Postal Service as First Class mail in  
an envelope addressed to: Mail Stop \_\_\_\_\_,  
Commissioner for Patents, P.O. Box 1450,  
Alexandria, VA 22313-1450,  
on this 3 day of March, 2006.

By [Signature]

03/07/2006 10:00:00 00000000 10010448

01.FG:1005


100.00 02

This Supplemental Information Disclosure Statement under 37 C.F.R. §1.56, §1.97 and §1.98 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these citations constitute prior art under 35 U.S.C. §102 or §103.

The Commissioner is hereby authorized to charge any additional fees in connection with this Supplemental Information Disclosure Statement to Deposit Account No. 03-1664. This, however, is not an authorization to pay Issue Fee.


Respectfully submitted,

By:

  
\_\_\_\_\_  
Young J. Suh  
Attorney for Applicants  
Reg. No. 41,337

March 3, 2005

CHIRON CORPORATION  
Intellectual Property - R440  
P.O. Box 8097  
Emeryville, California 94662-8097  
(510) 923-2706  
(510) 655-3542 (fax)



FORM PTO-1449 (Modified)	U.S. Dept. of Commerce Patent and Trademark Office	Pat. Docket No.: 16166.003	Serial No.: 10/010,448
INFORMATION DISCLOSURE CITATION		Applicants: Wolfe <u>et al.</u>	
(Use several sheets if necessary)		Filing Date: November 7, 2001	Group: 1646

## U.S. PATENT DOCUMENTS

*Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

	Document Number	Publ. Date	Country	Class	Subclass	Trans-Yes	lation No

## OTHER CITATIONS (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	Herberman <u>et al.</u> , "Augmentation by Interferon of Human Natural and Antibody-Dependent Cell-Mediated Cytotoxicity" <u>Nature</u> 277:221-223, January 1979
CB	Williams <u>et al.</u> , "Natural Occurrence of 2-5A in Interferon-Treated EMC Virus-Infected L Cells" <u>Nature</u> 282:582-586, 1979
CC	Anderson <u>et al.</u> , "Specific Binding of <sup>125</sup> I-Human Interferon-γ to High Affinity Receptors of Human Fibroblasts" <u>J. Biological Chemistry</u> 257(19):11301-11304, 1982
CD	Fellous <u>et al.</u> , "Interferon-Dependent Induction of mRNA for the Major Histocompatibility Antigens in Human Fibroblasts and Lymphoblastoid Cells" <u>Proc. Natl. Acad. Sci.</u> 79:3082-3086, May, 1982
CE	Czarniecki <u>et al.</u> , "Syneristic Antiviral and Antiproliferative Activities of <i>Escherichia coli</i> -Derived Human Alpha, Beta, and Gamma Interferons" <u>J. Virology</u> 49(2):490-496, February 1984
CF	Mark <u>et al.</u> , "Site-Specific Mutagenesis of the Human Fibroblast Interferon Gene" <u>Proc. Natl. Acad. Sci. USA</u> 81:5662-5666, September, 1984

Examiner	Date Considered
----------	-----------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.